GenomeWeb

1 day ago | genomeweb.com | Adam Bonislawski

NEW YORK – Seer reported first quarter revenues of $4.2 million after the close of market on Tuesday, up 35 percent from $3.1 million in the year-ago period. For the three months ended March 31, the Redwood City, California-based proteomics technology firm posted $2.9 million in product revenue, up 71 percent from $1.7 million a year ago. Service revenue totaled $1.2 million, up nearly threefold from $408,000 in Q1 2024, while other revenue was $60,000, up 67 percent from $36,000 a year ago.

2 days ago | genomeweb.com | Andrew P. Han

NEW YORK – The US Court of Appeals for the Federal Circuit has paved the way for yet another round of legal fighting over foundational CRISPR-Cas9 patents awarded to genome editing pioneers Jennifer Doudna and Feng Zhang, respectively.

2 days ago | genomeweb.com | Adam Bonislawski

NEW YORK – Citing tariffs, cuts to academic funding, and lower biopharma spending, Quanterix on Monday lowered its full-year 2025 revenue guidance to between $120.0 million and $130.0 million. The guidance, which excludes revenue from its Lucent Diagnostics business and the expected acquisition of Akoya Biosciences, would represent a year-over-year decline of 5 percent to 13 percent.

1 week ago | genomeweb.com | Andrew P. Han

NEW YORK – Illumina has raised prices on all products and services for US and European customers in response to "tariff and supply chain trends." In a communication to customers obtained by GenomeWeb, Illumina said US customers would see a "surcharge" on all new orders: 5 percent for consumables, between 2 percent and 9 percent on instruments, and 3.5 percent on most services. Should the tariff situation change, "we will adjust accordingly," Illumina told customers.

1 week ago | genomeweb.com | Julia Karow

NEW YORK – In less than six weeks, the Trump Administration canceled more than $544 million worth of unexpended funding from active National Institutes of Health grants, according to an analysis by researchers at Yale School of Medicine and Harvard Medical School. While the study didn't shed light on the types of research topics targeted, it is one of the first attempts to systematically tally the effects of President Trump's cuts to ongoing NIH funding.